Boehringer Ingelheim obtains interim injunction against four Indian drug cos from selling its diabetes drug

BI said the injunctions restrain the domestic pharma companies from infringing the patent of Linagliptin by advertising, launching, making, using, offering for sale, selling, importing or exporting in any form in India either by themselves or through their directors, partners licenses, stockist and distributors, agents etc., jointly and severally until the next date of hearing.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/hNvEG14
via IFTTT